OGAB
DEAD

Serial Number

79272216

Owner

Synplogen Co., Ltd.

Attorney

Rebeccah Gan

Filing Date

Aug 22, 2019

Add to watchlist:

No watchlists yet
View on USPTO

OGAB Trademark

Serial Number: 79272216

OGAB is a trademark filed by Synplogen Co., Ltd. on August 22, 2019. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Synplogen Co., Ltd. (4 trademarks)

1-1 Rokkodai-cho,

Entity Type: 03

Trademark Details

Filing Date

August 22, 2019

Registration Date

Not Registered

Goods & Services

Research and development relating to DNA synthesis technology; technical advisory services and information technology consulting services relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services and information technology consulting services relating to genome synthesis technology; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection and research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; information technology services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection and research relating to medical treatment or medical technology with genome synthesis technology; information technology consulting services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others for scientific research purposes; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; DNA sequence design services for scientific research purposes; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jul 30, 2022 NREP
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Apr 20, 2022 LIMN
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 21, 2022 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Mar 2, 2022 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 2, 2022 FICR
LIMITATION OF GOODS RECEIVED FROM IB
Feb 5, 2022 LIMG
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 10, 2021 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 21, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 21, 2021 OPNR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 3, 2021 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Mar 2, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 2, 2021 ABN2
REFUSAL PROCESSED BY IB
Sep 18, 2020 RFNT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 17, 2020 GNRN
NON-FINAL ACTION E-MAILED
Aug 17, 2020 GNRT
NON-FINAL ACTION WRITTEN
Aug 17, 2020 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 16, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 16, 2020 CRFA
ASSIGNED TO LIE
Jul 10, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 30, 2020 TROA
REFUSAL PROCESSED BY IB
Jan 17, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 30, 2019 RFCS
REFUSAL PROCESSED BY MPU
Dec 30, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 4, 2019 RFCR
NON-FINAL ACTION WRITTEN
Dec 3, 2019 CNRT
NON-FINAL ACTION WRITTEN
Dec 3, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Nov 26, 2019 MAFR
ASSIGNED TO EXAMINER
Nov 22, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 22, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 21, 2019 REPR